Clinical trials: Cerebral Small Vessel Diseases
Stroke, Lacunar, Stroke, Acute Ischemic
Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with…
- Conditions
- Stroke, Lacunar, Stroke, Acute Ischemic, Cerebral Small Vessel Diseases
- Trial name
- NCT07252544
- Testing
- Isosorbide Mononitrate, Butylphthalide
- Volunteers
- 3,156 people
- Sponsor
- Beijing Tiantan Hospital
Fabry Disease, Lysosomal Storage Diseases
A Fabry Disease Gene Therapy Study
This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
- Trial name
- MARVEL1 (NCT04040049)
- Testing
- FLT190
- Where
- 13 sites in United States, Austria and 5 more
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
Fabry Disease
Screening of Fabry Disease in Patients With GI Symptoms
Fabry disease screening study in patients diagnosed with gastrointestinal tract (GIT) disease, i.e. with the diagnosis of non-infectious inflammatory bowel disease, functional dyspepsia or irritable bowel syndrome in particular…
- Trial name
- GiFD (NCT04184986)
- Testing
- dry blood test
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- General University Hospital, Prague
Metabolic Disease, Fabry Disease
Getting Global Rare Disease Insights Through Technology Study
This project is a randomized controlled trial to use a mobile health journal, called Zamplo (formerly known as MyHealthJournal or ZoeInsights), to record patient reported outcomes (PROM) in patients with metabolic disorders.
- Conditions
- Metabolic Disease, Fabry Disease, Gaucher Disease, Pompe Disease
- Trial name
- GRIT (NCT04758130)
- Testing
- Zamplo Digital Health Platform
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- M.A.G.I.C. Clinic LTD
Polyarteritis Nodosa, Microscopic Polyangiitis
CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
To assess the efficacy of systemic corticosteroids alone as first-line treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors as defined by the five-factor score (FFS=0), and to compare the…
- Trial name
- NCT00400075
- Testing
- azathioprine, cyclophosphamide
- Where
- Switzerland
- Volunteers
- 124 people
- Sponsor
- Hospices Civils de Lyon
Angiokeratomas, Chronic Kidney Disease
Biomarker for Patients With Fabry Disease (BioFabry)
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
- Conditions
- Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss
- Trial name
- BioFabry (NCT02778295)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Dysphagia, Cerebral Small Vessel Diseases
Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease
A prospective study was conducted on 84 CSVD patients with dysphagia and cognitive impairment. They were divided into the comparison group and observation group evenly.
- Conditions
- Dysphagia, Cerebral Small Vessel Diseases, Cognitive Impairment
- Trial name
- NCT06176404
- Testing
- Stellate ganglion block, Rehabilitation therapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Zeng Changhao
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Ischemic Heart Disease, Microvascular Coronary Artery Disease
The Cerebral-Coronary Connection (C3) Study
This is a prospective cohort blinded study with the aim to investigate the prevalence and clinical impact of coronary microcirculatory dysfunction (CMD) in patients with ischemic heart disease, and its association with cerebral…
- Conditions
- Ischemic Heart Disease, Microvascular Coronary Artery Disease, Depression, Endothelial Dysfunction
- Trial name
- C3 (NCT04131075)
- Testing
- Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Instituto de Salud Carlos III
Small Vessel Cerebrovascular Disease
Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial
Chronic damage to small blood vessels deep in the brain is seen in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and almost half of patients with…
- Trial name
- OxHARP (NCT03855332)
- Testing
- Sildenafil, Cilostazol
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Oxford
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
The KHENERGYC Study
This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of…
- Conditions
- Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, MELAS, Subacute Necrotizing Encephalomyelopathy
- Trial name
- NCT04846036
- Testing
- Sonlicromanol
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Khondrion BV
Stroke, Acute, Stroke
Evaluation of Small Vessel Disease by 3D-rotational Angiography
This study is aimed to elucidate the factors affecting the remodeling process of arteriolosclerosis under current practice recommendations.
- Conditions
- Stroke, Acute, Stroke, Small Vessel Cerebrovascular Disease, Ischemic Stroke
- Trial name
- NCT04611906
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Fabry Disease
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
The objective of CLI-06657AA1-04 (formerly PB-102-F60) was to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry…
- Trial name
- NCT03566017
- Testing
- pegunigalsidase alfa
- Where
- 30 sites in United States, Australia and 11 more
- Volunteers
- 97 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cerebral Small Vessel Disease
Neural Correlates (EEG and fMRI) of Gait in Small Vessel Disease
What is the purpose of this study? This observational study is being done to understand how cerebral small vessel disease (SVD) affects walking and balance.
- Trial name
- doesn't exist (NCT07372937)
- Testing
- No Intervention: Observational
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Stroke, Physical Therapy Modalities
Is the 6-Minute Walking Test Combined With an IMU Useful in Stroke Rehabilitation Assessment?
This Observational study aims at the evaluation of stroke subjects with an inertial measurement unit (IMU) during the execution of a 6-Minute Walking test, to evaluate the associations between the kinematic parameters retrieved…
- Conditions
- Stroke, Physical Therapy Modalities, Gait Analysis
- Trial name
- NCT04529642
- Testing
- Inertial Measurement Unit evaluation
- Where
- Italy
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Fabry Disease
Anderson-Fabry Disease Fitness Improvement Training
This study will evaluate physical function, cardiorespiratory fitness, muscle strength, and quality of life in patients with Fabry disease and assess the effects of a 12-week physiotherapy-led exercise programme.
- Trial name
- A-FAD-FIT (NCT07495410)
- Testing
- Physiotherapy exercise programe
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- General University Hospital, Prague
Fabry Disease
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene.
- Trial name
- NCT05698901
- Testing
- Agalsidase beta
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Mackay Memorial Hospital
Fabry Disease
Pulmonary Involvement in Patients With Fabry Disease
The objective of this study is to investigate whether Agalsidase alpha, a drug commonly prescribed in patients with Fabry disease, is associated with improvement of the pulmonary involvement.
- Trial name
- NCT01632111
- Testing
- Lung function measurement
- Where
- Switzerland
- Volunteers
- 110 people
- Sponsor
- University of Zurich
Fabry Disease
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study evaluating kidney Gb3 inclusions (and other histologic lesions) in male…
- Trial name
- NCT03737214
- Testing
- Lucerastat
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 107 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.